PEBP1 amplifies mitochondrial dysfunction-induced integrated stress response.

Mitochondrial dysfunction is involved in numerous diseases and the aging process. The integrated stress response (ISR) serves as a critical adaptation mechanism to a variety of stresses, including those originating from mitochondria. By utilizing mass spectrometry-based cellular thermal shift assay (MS-CETSA), we uncovered that phosphatidylethanolamine-binding protein 1 (PEBP1), also known as Raf kinase inhibitory protein (RKIP), is thermally stabilized by stresses which induce mitochondrial ISR.

"Am I in 'Suboptimal Health'?": The Narratives and Rhetoric in Carving out the Grey Area Between Health and Illness in Everyday Life.

This paper examines the concept of 'suboptimal health' (subhealth, ), a term popularised by traditional Chinese medicine (TCM) professionals and widely used in public health discourses in China at the turn of the century. Despite criticisms of it being a commercial buzzword, subhealth provides a unique lens for individuals to articulate their health experiences concerning work and life pressures. Through virtual ethnography on Chinese social media such as Weibo and interviews, this study explores the usage and implications of subhealth in everyday life.

Abnormal network homogeneity in patients with bipolar disorder in attention network.

Bipolar disorder (BD) is a complex psychiatric condition marked by significant mood fluctuations that deeply affect quality of life. Understanding the neural mechanisms underlying BD is critical for improving diagnostic accuracy and developing more effective treatments. This study utilized resting-state functional magnetic resonance imaging (rs-fMRI) to investigate functional connectivity within the ventral and dorsal attention networks in 52 patients with BD and 51 healthy controls.

Corrigendum: Specific detection of duck adeno-associated virus using a TaqMan-based real-time PCR assay.

[This corrects the article DOI: 10.3389/fvets.2024.

Potential therapeutic strategies for MASH: from preclinical to clinical development.

Current treatment paradigms for metabolic dysfunction-associated steatohepatitis (MASH) are based primarily on dietary restrictions and the use of existing drugs, including anti-diabetic and anti-obesity medications. Given the limited number of approved drugs specifically for MASH, recent efforts have focused on promising strategies that specifically target hepatic lipid metabolism, inflammation, fibrosis, or a combination of these processes. In this review, we examined the pathophysiology underlying the development of MASH in relation to recent advances in effective MASH therapy.